Sandusky, OH – October 15, 2020 – — PAO Group, Inc. (OTC PINK: PAOG) today published a progress update on the company’s ongoing initiative to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA). PAOG anticipates entering into an agreement with a contract research organization (CRO) within the next two weeks. The CRO engagement will be a major breakthrough in advancing PAOG’s RespRx treatment for Chronic Obstructive Pulmonary Disease (COPD) toward FDA approval.
On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC PINK: KALY). RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method – U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.”
In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis.
In conjunction with PAOG’s acquisition of RespRx, the company also recently acquired a hemp cultivation business from Puration, Inc. (OTC PINK: PURA) to develop a proprietary cultivar to support PAOG’s cannabis pharmaceutical treatment objectives.
PAOG has announced plans with PURA to expand upon PAOG’s hemp cultivation business to develop a proprietary hemp cultivar. PAOG and PURA are partnering on PURA’s Farmersville Brands initiative.
PAOG’s Farmersville cultivar development operation will include a lab and an environmentally controlled indoor growing facility. PAOG is working with current cultivars to evolve and produce an ideal plant with full spectrum, high CBD yields to support ongoing RespRx development and to support future CBD pharmaceutical developments.
PAOG is exploring opportunities to engage with university research in partnership with its hemp cultivar development initiative.
PURA recently announced a year long initiative to transition PURA from a CBD sports beverage manufacturer into a hemp conglomerate built on lifestyle brand with a broad CBD consumer products reach, and a leading industrial hemp initiative. The brand name is Farmersville Brands and as part of their strategy, PURA has entered into a letter of intent (LOI) agreement to acquire 72 acers of agricultural property in Farmersville, Texas. PURA’s year long initiative includes plans to see the Farmersville Brand strategy infused with a $100 million investment.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.